BTG plc (BTG) Receives Consensus Rating of “Buy” from Brokerages
BTG plc (LON:BTG) has received a consensus recommendation of “Buy” from the nine analysts that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is GBX 777.57 ($10.40).
Several analysts recently weighed in on the company. JPMorgan Chase & Co. restated a “neutral” rating on shares of BTG in a research report on Friday, October 6th. Deutsche Bank restated a “buy” rating and set a GBX 775 ($10.36) price objective on shares of BTG in a research report on Thursday, September 21st. Numis Securities restated a “buy” rating and set a GBX 900 ($12.03) price objective on shares of BTG in a research report on Wednesday, September 20th. Finally, Peel Hunt restated a “hold” rating and set a GBX 680 ($9.09) price objective on shares of BTG in a research report on Wednesday, September 20th.
BTG (BTG) opened at GBX 758 ($10.14) on Friday. The firm has a market cap of $2,900.00 and a price-to-earnings ratio of 3,989.47. BTG has a fifty-two week low of GBX 528.36 ($7.06) and a fifty-two week high of GBX 784 ($10.48).
COPYRIGHT VIOLATION NOTICE: This news story was posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/05/btg-plc-btg-receives-consensus-rating-of-buy-from-brokerages.html.
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.